KOD vs KROS

Kodiak Sciences Inc vs Keros Therapeutics, Inc. — Valuation Comparison 2026

By CirclFi Research Team · Updated 2026-06-03 · Data from SEC EDGAR, FRED & GDELT

Quick Summary — KROS scores higher on quality with 8.6/10 vs KOD's 4.8/10. KOD trades at $33.22 while KROS trades at $10.55. Both analyzed daily using SEC EDGAR data across 13 institutional models.

KOD

Biotechnology
Kodiak Sciences Inc
Quality
4.8
out of 10
Value Trap
12
SAFE
Price
$33.22
Last close
Models
10/13
Active
VS

KROS

Biotechnology
Keros Therapeutics, Inc.
Quality
8.6
out of 10
Value Trap
6
SAFE
Price
$10.55
Last close
Models
8/13
Active
KOD
2 models active
Quality 4.8/10 — below average
KROS
Earnings Power Value sees +278.0% upside
Limited to 2/13 visible models

KOD vs KROS — Fair Value Comparison

KOD
$0$13$26$39 Price$33.22 Bayesian …$10.92 (-67.1%) Earnings …$23.98 (-46.5%)
KROS
$0$16$31$47 Price$10.55 Earnings …$39.88 (+278.0%) Dynamic N…$20.22 (+91.6%)
Market Price Model 1 Model 2

Model-by-Model Comparison

ModelType KOD Fair ValueKOD Upside KROS Fair ValueKROS Upside
Bayesian DCF Intrinsic $10.92 -67.1% — —
Earnings Power Value Intrinsic $23.98 -46.5% $39.88 +278.0%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.57 -89.2% $20.22 +91.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%

KOD vs KROS — Which Stock Is More Undervalued in 2026?

KROS scores higher with a 8.6/10 quality rating vs KOD's 4.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do KOD and KROS Valuations Compare?

KOD currently trades at $33.22 while KROS trades at $10.55. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily for both companies.

Quality of Company: KOD vs KROS

KOD earns a Quality of Company score of 4.8/10 compared to KROS's 8.6/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: KOD vs KROS

KOD carries a SAFE value trap risk (12/100) while KROS shows SAFE risk (6/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.

Both in Biotechnology

Both KOD and KROS operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare KOD vs KROS differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo  ·  FactSet: ~$1,000/mo  ·  CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

KOD
View Full Kodiak Sciences Inc Analysis →
KROS
View Full Keros Therapeutics, Inc. Analysis →
See all Biotechnology stocks →